Covid-19

#Covid-19 #Immunology / Virology & Vaccines

Interim clinical trial results of NIH-Moderna COVID-19 vaccine show 94% efficacy

The investigational NIH-Moderna COVID-19 vaccine mRNA-1273 has been found to be safe and effective at preventing symptomatic COVID-19 in adults. This is according to the interim results reviewed by an independent data and safety monitoring board (DSMB) overseeing the Phase III trial of the investigational COVID-19 vaccine mRNA-1273. The interim… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Johnson & Johnson starts second global phase III trial of Janssen COVID-19 vaccine candidate

The Janssen COVID-19 vaccine candidate leverages the company’s AdVac technology platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac technology platform has been used to vaccinate more than 110,000 people to date across… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AI / data analytics / healthtech / informatics #Covid-19 #Drug development

Is virtual reality the new tool for COVID-19 drug design?

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus – and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Medicago and GSK start of Phase II/III clinical trials of adjuvanted COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are starting Phase II/III clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase I results, Medicago has decided to launch the Phase II/III clinical trial with GSK’s pandemic… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

CureVac’s COVID-19 vaccine candidate, suitable for standard fridge temperature logistics 

CureVac says its mRNA-based COVID-19 vaccine candidate, CVnCoV, remains stable and within defined specifications for at least three months when stored at a standard refrigerator temperature of +5°C (+41°F) and up to 24 hours as ready-to-use vaccine when stored at room temperature. “Transport and storage of vaccines requiring ultra-low temperature… Read More

#Covid-19 #News

#Clinical specialities #Covid-19 #Pneumonia

Campaign and conference shine light on importance of pneumonia research

The PneumoLight campaign, in collaboration with Pfizer – and coinciding with World Pneumonia Day – will see 232 buildings and monuments from 48 different countries will be illuminated in blue. The project involves Dr. Catia Cilloniz, a researcher at the Hospital Clínic of Barcelona, the University of Barcelona (UB), the Barcelona… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Life sciences report highlights implications of early COVID-19 vaccines data

FinnCap’s latest Rude Health Life Sciences Sector Report focuses on the implications of early COVID-19 vaccine data. This comes as Pfizer and BioNTech have announced their COVID-19 vaccine candidate has so far been found to be 90% effective in preventing COVID-19. Mark Brewer, Director of Research for finnCap, commented: "While the… Read More

#Business & Investment #Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Croda contract for Pfizer COVID-19 vaccine

Croda, the speciality chemical company has entered into an agreement with Pfizer to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract runs for five years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

It’s never been more important to talk about vaccines, says head of pharma organisation

Richard Torbett, Chief Executive, ABPI says vaccines are one of our best hopes for eradicating COVID-19 and why the ABPI is launching a campaign to highlight this. “COVID-19 has put shone a spotlight on the pharmaceutical industry like never before. Millions of people all over the world are living under… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Russia says Sputnik V vaccine against COVID-19 phase III clinical trials shows 92% efficacy

The National Research Center for Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced that the Sputnik V vaccine demonstrated high efficacy of 92%. The human adenoviral vectors vaccine against coronavirus was registered on the 11 August under the emergency use authorisation mechanism. The confirmation… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine trial results: a watershed moment says immunology expert

The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis has shown. The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”. The analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Daniel Davis,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Pfizer and BioNTech vaccine COVID-19 candidate found to be more than 90% effective

Pfizer and BioNTech have announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #CRISPR #High throughput screening

Mammoth Biosciences agreements to commercialise CRISPR-based SARS CoV-2 test

Mammoth Biosciences has signed agreements with MilliporeSigma and Hamilton Company targeting commercialisation of a high-throughput CRISPR-based SARS CoV-2 test. The test leverages Mammoth’s DETECTR BOOST platform and will provide a sample-to-answer turnkey solution for commercial laboratories to enable an increase in testing capacity. As laboratories face limited capacity and testing… Read More

#Covid-19 #News